Phuturdex › Diseases › Neurocognitive Disorders
Drugs in development · updated 30 October 2026
Neurocognitive Disorders: drugs in development
As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for neurocognitive Disorders. 5 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| GNR-055 | II–III | 1 | NCT05208281 |
| ML-007C-MA | II | 2 | NCT06887192 |
| Neflamapimod | II | 1 | NCT07033481 |
| LY3954068 | I | 1 | NCT06297590 |
| NIO752 | I | 1 | NCT05469360 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | III | 3 | NCT05508789 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| Medical airMedical Air, Usp® | II | 1 | NCT06382389 |
| MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride® | II | 1 | NCT06638710 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | I | 1 | NCT06297590 |
Sorted by most advanced phase and number of active trials.
All 10 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Alzheimer's disease 157 drugs
- Cognitive dysfunction 94 drugs
- Dementia 54 drugs
- Emergence delirium 18 drugs
- Huntington's disease 14 drugs
- Delirium 14 drugs
- Amyloid 9 drugs
- Inflammation 85 drugs
- Frontotemporal dementia 11 drugs
- Parkinson's disease 104 drugs
- Neurodegenerative Diseases 25 drugs
- Down syndrome 36 drugs
Broader categories
- Mental disorder 24 drugs
- Neurologic Manifestations 15 drugs
- Neurobehavioral manifestation 8 drugs
- Nutritional and metabolic diseases 5 drugs
- Cognition Disorders 6 drugs
- Metabolic disease 30 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D019965 “Neurocognitive Disorders”.